Shanton Pharma Achieves Key Milestone with FDA for Gout Treatment in the U.S. Shanton Pharma has successfully concluded an End-of-Phase 2 meeting with the FDA for its novel gout treatment, SAP-001, marking a crucial development in their clinical program.

Shanton Pharma Achieves Key Milestone with FDA for Gout Treatment in the U.S. #USA #Princeton #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma Achieves Critical Milestone with FDA for Gout Treatment Development Shanton Pharma announces the successful completion of an End-of-Phase 2 meeting with the FDA for its gout treatment, SAP-001.

Shanton Pharma Achieves Critical Milestone with FDA for Gout Treatment Development #USA #Princeton #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma Secures Fast Track Designation from FDA for Innovative Gout Treatment Shanton Pharma announces FDA’s Fast Track designation for their gout treatment SAP-001, enhancing regulatory review for unmet medical needs in refractory gout patients.

Shanton Pharma Secures Fast Track Designation from FDA for Innovative Gout Treatment #USA #SAP-001 #Shanton_Pharma #Refractory_Gout #Princeton,_New_Jersey

Shanton Pharma's SAP-001 Gains Fast Track Designation from FDA for Gout Treatment Shanton Pharma announces its investigational drug SAP-001 for gout has received Fast Track designation from the FDA, aiming to speed up treatment availability.

Shanton Pharma's SAP-001 Gains Fast Track Designation from FDA for Gout Treatment #USA #Princeton #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma to Unveil Promising Phase 2b Data on SAP-001 for Gout at EULAR 2025 Shanton Pharma will present phase 2b trial results for SAP-001 in refractory gout patients at EULAR 2025, highlighting its effectiveness and potential.

Shanton Pharma to Unveil Promising Phase 2b Data on SAP-001 for Gout at EULAR 2025 #USA #Barcelona #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma to Unveil Key Findings on SAP-001 for Gout at EULAR 2025 Congress Shanton Pharma reveals plan to present key data from its Phase 2b study on SAP-001, a new treatment for refractory gout, at EULAR 2025.

Shanton Pharma to Unveil Key Findings on SAP-001 for Gout at EULAR 2025 Congress #USA #Barcelona #Gout_Treatment #SAP-001 #Shanton_Pharma

Shanton Pharma's Phase 2b Trial Shows Promising Results for Gout Treatment Shanton Pharma has released positive data from its Phase 2b study of SAP-001, an innovative treatment for patients with refractory gout, showing remarkable efficacy and safety.

Shanton Pharma's Phase 2b Trial Shows Promising Results for Gout Treatment #None #SAP-001 #Shanton_Pharma #Refractory_Gout